Skip to main content

Table 1 Demographic characteristics of 42 spondyloarthritis patients

From: The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients

Characteristic Total (42 patients) Without ADA (31 patients) With ADA (11 patients) pvalue
Sex, male 23 (54.8%) 16 (51.6%) 7 (63.6%) 0.726
Age 49.60 ± 10.46 51.26 ± 10.08 44.91 ± 10.53 0.084
HLA-B27-positivea 23/36 (64%) 17/27 (63%) 6/9 (66.7%) 0.841
Disease duration (years) 12.24 ± 8.23 11.61 ± 8.04 14 ± 8.92 0.416
Baseline ASDAS 3.42 ± 1.01 3.52 ± 1.03 3.14 ± 0.95 0.399
Concomitant treatment     
   Methotrexate 9 (21.5%) 8 (25.8%) 1 (9.1%) 0.498
   Other DMARDs 10 (23.8%) 5 (16.1%) 5 (45.4%) 0.115
   Methotrexate + other 1 (4,7%) 2 (6.4%) 0 (0%) 0.599
DMARDs     
   Monotherapy 21 (50%) 16 (51.7%) 5 (45.5%) 0.126
   Corticosteroid therapy 15 (35.7%) 9 (29%) 6 (50%)  
  1. Data presented as n (%) or mean ± standard deviation. ADA, anti-drug antibodies; ASDAS, Ankylosing Spondylitis Disease Activity Score; DMARD, disease-modifying anti-rheumatic drug. an/total number (%).